Incyte Deal Further Validates Calithera Biosciences (CALA) Program - JMP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
January 30, 2017 6:45 AM ESTIncyte gains worldwide rights to CB-1158 for hematology and oncology indications Calithera to receive a $45 million up-front payment and an $8 million equity investment Incyte and Calithera to co-fund global development of CB-1158; Calithera eligible to receive share of profits in the U.S., potential milestones and royalties on future sales of CB-1158  Calithera conference call scheduled today at 8:30 a.m. ET, 5:30 a.m. PT
WILMINGTON, Del. AND SOUTH SAN FRANCISCO, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Incyte Corporation (NASDAQ: INCY) and Calithera... More
